Edwards Lifesciences Co. (NYSE:EW) Position Trimmed by Curi RMB Capital LLC

Curi RMB Capital LLC reduced its holdings in Edwards Lifesciences Co. (NYSE:EW) by 23.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 17,838 shares of the medical research company’s stock after selling 5,457 shares during the quarter. Curi RMB Capital LLC’s holdings in Edwards Lifesciences were worth $1,321,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Crowley Wealth Management Inc. bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $26,000. Millstone Evans Group LLC acquired a new position in Edwards Lifesciences during the 4th quarter valued at approximately $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Edwards Lifesciences during the 4th quarter worth $30,000. Roble Belko & Company Inc acquired a new stake in Edwards Lifesciences in the fourth quarter worth $46,000. Finally, Catalyst Capital Advisors LLC bought a new stake in Edwards Lifesciences in the fourth quarter valued at $54,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price objective for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Piper Sandler lifted their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a report on Wednesday, February 12th. Canaccord Genuity Group increased their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. Wolfe Research downgraded Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of “Hold” and an average target price of $78.55.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 9,500 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,189,770.56. The trade was a 16.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bernard J. Zovighian sold 6,164 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the sale, the chief executive officer now owns 59,083 shares in the company, valued at approximately $4,106,859.33. The trade was a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,853 shares of company stock worth $5,163,062 over the last three months. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $71.56 on Monday. The stock has a market capitalization of $42.07 billion, a PE ratio of 10.27, a P/E/G ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The business has a fifty day moving average price of $71.31 and a two-hundred day moving average price of $70.92.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, equities analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.